1、Finance Report 2024Finance in BriefPharmaceuticals Key resultsDiagnosticsGroup20242023Sales CER growth%Core operating proft margin%of sales2024202320242023+8.2+6.0+3.512.847.745.716.816.734.432.8+7.0+0.6 20242023%change%change%of sales%of sales(CHF m)(CHF m)(CHF)(CER)20242023IFRS results Sales60,495

2、58,716+3+7 Operating profit13,41715,39513 622.226.2Net income9,18712,35826 1915.221.0Net income attributable to Roche shareholders8,27711,49828 2113.719.6Diluted EPS(CHF)10.3114.3128 20 Dividend per share(CHF)9.70 a)9.60+1 Core results Research and development13,04213,2371+121.622.5Core operating pr

3、ofit20,82319,240+8+1434.432.8Core EPS(CHF)18.8018.57+1+7 Free cash flow Operating free cash flow20,12115,768+28+3433.326.9Free cash flow15,33611,288+36+4325.419.2 20242023%change%change(CHF m)(CHF m)(CHF)(CER)Net debt(17,337)(18,699)716 Capitalisation70,81562,472+13+10 Debt34,65429,209+19+13 Equity3

4、6,16133,263+9+8a)Proposed by the Board of Directors.CER(Constant Exchange Rates).The percentage changes at constant exchange rates are calculated using simulations by reconsolidating both the 2024 and 2023 results at constant exchange rates(the average rates for the year ended 31 December 2023).For

5、the definition of CER see page 177.Core results and Core EPS(earnings per share).These exclude non-core items such as global restructuring plans and amortisation and impairment of goodwill and intangible assets.This allows an assessment of both the actual results and the underlying performance of th

6、e business.A full income statement for the Group and the operating results of the divisions are shown on both an IFRS and core basis.The core concept is fully described on pages 170173 and reconciliations between the IFRS and core results are given there.Free cash flow is used to assess the Groups a